Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Position Decreased by Treasurer of the State of North Carolina

Treasurer of the State of North Carolina reduced its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report) by 1.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,946 shares of the specialty pharmaceutical company’s stock after selling 501 shares during the quarter. Treasurer of the State of North Carolina’s holdings in Jazz Pharmaceuticals were worth $3,437,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Cape Investment Advisory Inc. increased its holdings in shares of Jazz Pharmaceuticals by 14,600.0% in the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock valued at $36,000 after buying an additional 292 shares in the last quarter. Covestor Ltd grew its holdings in shares of Jazz Pharmaceuticals by 676.5% in the 3rd quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company’s stock worth $51,000 after acquiring an additional 345 shares during the last quarter. Assetmark Inc. raised its position in shares of Jazz Pharmaceuticals by 37.1% during the fourth quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 119 shares during the period. Spire Wealth Management lifted its holdings in shares of Jazz Pharmaceuticals by 128.6% during the third quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company’s stock valued at $55,000 after purchasing an additional 238 shares during the last quarter. Finally, Headinvest LLC acquired a new position in shares of Jazz Pharmaceuticals in the 3rd quarter valued at $56,000. 89.14% of the stock is currently owned by institutional investors.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of the stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total transaction of $548,250.00. Following the transaction, the executive vice president now directly owns 36,629 shares of the company’s stock, valued at $4,016,369.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.40% of the stock is owned by company insiders.

Jazz Pharmaceuticals Stock Down 1.2 %

JAZZ opened at $104.48 on Wednesday. The company has a market capitalization of $6.59 billion, a PE ratio of 21.54, a price-to-earnings-growth ratio of 1.62 and a beta of 0.62. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.27 and a quick ratio of 1.90. Jazz Pharmaceuticals plc has a fifty-two week low of $103.01 and a fifty-two week high of $146.70. The business has a 50-day moving average of $110.63 and a 200-day moving average of $117.98.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing the consensus estimate of $3.53 by ($1.55). The business had revenue of $901.98 million for the quarter, compared to the consensus estimate of $938.99 million. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. Equities research analysts forecast that Jazz Pharmaceuticals plc will post 15.35 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on JAZZ shares. Cantor Fitzgerald restated an “overweight” rating and set a $180.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. HC Wainwright restated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, May 3rd. Piper Sandler raised their price objective on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. Needham & Company LLC restated a “buy” rating and issued a $222.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, May 2nd. Finally, JPMorgan Chase & Co. lifted their price target on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the company an “overweight” rating in a report on Friday, March 22nd. Two research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $192.75.

View Our Latest Research Report on JAZZ

Jazz Pharmaceuticals Company Profile

(Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Featured Articles

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.